Beijing Jiandakang New Drug Development

Beijing Jiandakang New Drug Development is a clinical-stage biotechnology company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic disorders, including type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH), as well as oncology and inflammatory diseases. Its lead candidate, JDK-814, is a potent GPR119 agonist currently being evaluated for its efficacy in glycemic control and metabolic improvement. By leveraging its expertise in medicinal chemistry and G protein-coupled receptor (GPCR) targeting, Beijing Jiandakang aims to address significant unmet medical needs in the global healthcare market.